

Chassis Organisms: Building Blocks for Synthetic Biology

Jin Miao*

Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China

Abstract

Chassis organisms serve as foundational platforms in synthetic biology, enabling the design and engineering of biological systems for diverse applications. These organisms, typically well-characterized microbes such as *Escherichia coli* and *Saccharomyces cerevisiae*, provide a stable and predictable environment for genetic modifications, facilitating the development of biosynthetic pathways, metabolic engineering, and biomanufacturing. The selection of an optimal chassis depends on factors such as genetic tractability, growth conditions, and biosafety. Advances in genome editing and synthetic biology tools have expanded the repertoire of chassis organisms, including minimal cells and non-model microbes, enhancing their utility in medicine, biofuel production, and environmental biotechnology. This article explores the role of chassis organisms in synthetic biology, highlighting their advantages, current developments, and future potential.

Keywords: Chassis organisms; Synthetic biology; Genetic engineering; Metabolic engineering; Minimal cells; Biomanufacturing; Biosensors; Microbial platforms; Biotechnology; Genome editing.

Introduction

Chassis organisms are the foundational "building blocks" of synthetic biology, serving as engineered hosts for the construction of novel biological systems and synthetic pathways. These organisms, often bacteria or yeast, are designed to act as vehicles or "chassis" to carry out specific tasks, such as producing biofuels, synthesizing pharmaceuticals, or degrading environmental pollutants. By modifying the genetic makeup of these organisms, scientists can harness their natural biological processes to perform a wide range of functions that are not typically seen in nature [1,2].

The concept of a chassis organism is central to synthetic biology, which seeks to design and construct new biological parts, systems, and organisms with predictable, engineered functions. These chassis organisms are carefully selected and engineered for their ability to reliably express foreign genes, grow under specific conditions, and integrate complex genetic circuits, offering a controlled environment for the development and testing of synthetic biological applications [3].

With advancements in genetic engineering, chassis organisms are becoming more versatile and efficient, allowing for the development of custom-built organisms tailored to meet specific industrial, medical, and environmental needs. As the field of synthetic biology progresses, chassis organisms will continue to play a vital role in unlocking new possibilities for biotechnology, paving the way for innovative solutions to some of the world's most pressing challenges [4].

Description

Chassis organisms are the foundational biological platforms used in synthetic biology to design and construct engineered biological systems. These organisms provide a stable and predictable environment for genetic modifications, enabling scientists to develop novel metabolic pathways, biosensors, and biomanufacturing processes. Traditionally, model organisms such as *Escherichia coli* and *Saccharomyces cerevisiae* have been the preferred chassis due to their well-characterized genetics, rapid growth, and ease of manipulation. However, with advancements in synthetic biology, alternative chassis organisms, including minimal cells, extremophiles, and non-model microbes, are gaining attention for their unique capabilities [5-7].

The selection of a chassis organism depends on factors such as genetic tractability, growth conditions, tolerance to environmental stresses, and biosafety considerations. Minimal genome organisms, such as *Mycoplasma mycoides* JCVI-syn3.0, represent a new class of synthetic biology chassis, stripped down to only essential genes, reducing complexity and enhancing the efficiency of engineered pathways. Other emerging chassis include cyanobacteria, which enable direct solar-driven biosynthesis, and extremophiles, which thrive in extreme conditions and hold potential for industrial applications in harsh environments. The ability to engineer these organisms expands the scope of synthetic biology, from drug development to sustainable biofuel production [8-10].

Discussion

The significance of chassis organisms in synthetic biology lies in their ability to support engineered genetic systems in a predictable and scalable manner. Microbial chassis such as *E. coli* have been extensively used in metabolic engineering to produce bioplastics, biofuels, and pharmaceuticals. Yeast, particularly *S. cerevisiae*, serves as an ideal platform for complex biosynthetic pathways, including the production of therapeutic proteins and secondary metabolites. These organisms have been genetically optimized to host synthetic circuits, offering reliable expression systems and high-yield bioproduction.

Beyond traditional microbial models, the use of minimal genome chassis provides a simplified yet highly efficient platform for synthetic biology applications. The development of *Mycoplasma mycoides* JCVI-syn3.0 demonstrated that a living cell can function with a minimal set of genes, making it an attractive host for designing tailor-made biological systems with reduced interference from unnecessary genetic

***Corresponding author:** Jin Miao, Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China, E-mail: jinmiao23@gmail.com

Received: 03-Jan-2025, Manuscript No: jbtbm-25-162069, **Editor Assigned:** 09-Jan-2025, Pre QC No: jbtbm-25-162069 (PQ), **Reviewed:** 17-Jan-2025, QC No: jbtbm-25-162069, **Revised:** 27-Jan-2025, Manuscript No: jbtbm-25-162069 (R), **Published:** 31-Jan-2025, DOI: 10.4172/2155-952X.1000425

Citation: Jin M (2025) Chassis Organisms: Building Blocks for Synthetic Biology. J Biotechnol Biomater, 15: 425.

Copyright: © 2025 Jin M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

elements. Meanwhile, non-model microbes such as cyanobacteria and extremophiles open new avenues for biotechnology by offering capabilities such as photosynthetic biosynthesis and resistance to extreme conditions, which are beneficial for industrial and environmental applications.

However, the use of chassis organisms is not without challenges. Engineering non-model organisms remains complex due to the lack of standardized genetic tools and the unpredictability of biological systems. Synthetic circuits can impose metabolic burdens on host organisms, leading to reduced growth rates and unintended mutations. Furthermore, ensuring genetic stability and avoiding cross-talk between engineered and native pathways require sophisticated design strategies. Advances in CRISPR-based genome editing, machine learning-guided metabolic engineering, and systems biology approaches are helping address these challenges, enabling more precise and efficient engineering of chassis organisms.

Another crucial consideration is biosafety and ethical concerns associated with synthetic biology. The creation of highly engineered organisms raises regulatory challenges, particularly regarding their environmental impact and containment. Ensuring that synthetic biology applications remain safe, sustainable, and ethical will be essential as these technologies continue to evolve.

Conclusion

Chassis organisms serve as the fundamental building blocks of synthetic biology, enabling the controlled design and execution of engineered biological functions. While traditional models like *E. coli* and yeast remain indispensable, emerging chassis such as minimal genome cells and extremophiles are expanding the possibilities of synthetic biology. Overcoming challenges related to genetic stability, metabolic burden, and regulatory concerns will be key to unlocking the full potential of these organisms.

The future of chassis organisms in synthetic biology will be driven by interdisciplinary advancements in genome engineering, artificial

intelligence, and systems biology. The ability to design and optimize organisms with tailored functionalities will revolutionize medicine, biofuel production, environmental remediation, and industrial biotechnology. As synthetic biology continues to advance, chassis organisms will play a pivotal role in shaping a more sustainable and innovative bio-based economy.

References

1. Abdulle A, Chow JC (2019) Contrast enhancement for portal imaging in nanoparticle-enhanced radiotherapy: A Monte Carlo phantom evaluation using flattening-filter-free photon beams. *Nanomaterials* 9: 920.
2. Baig N, Kammakam I, Falath W (2021) *Nanomaterials: A review of synthesis methods, properties, recent progress, and challenges*. *Mater Adv* 2: 1821-1871.
3. Ahmad A, Alsaad A, Al-Bataineh Q M, Albataineh Z, Alizy K A, et al. (2021) Synthesis and characterization of ZnO NPs-doped PMMA-BDK-MR polymer-coated thin films with UV curing for optical data storage applications. *Polymer Bull.* 78: 1189-1211.
4. Ahmad A, Senapati S, Khan M I, Kumar R, Ramani R, et al. (2003) Intracellular synthesis of gold nanoparticles by a novel alkalotolerant actinomycete. *Rhodococcus* species. *Nanotechnology* 14: 824.
5. Ahmad T, Wani IA, Ahmed, Al-Hartomy O A (2014) Effect of gold ion concentration on size and properties of gold nanoparticles in TritonX-100 based inverse microemulsions. *Appl Nanosci* 4: 491-498.
6. Ajitha B, Reddy YAK, Reddy PS (2015) Green synthesis and characterization of silver nanoparticles using *Lantana camara* leaf extract. *Mater Sci Eng C* 49: 373-381.
7. Al-Dhabi NA, Mohammed Ghilan AK, Arasu MV (2018) Characterization of silver nanomaterials derived from marine *Streptomyces* sp. al-dhabi-87 and its in vitro application against multidrug resistant and extended-spectrum beta-lactamase clinical pathogens. *Nanomaterials* 8: 279.
8. Amendola V, Meneghetti M (2009) Laser ablation synthesis in solution and size manipulation of noble metal nanoparticles. *Phys Chem Chem Phys* 11: 3805-3821.
9. Anjum S, Hashim M, Malik SA, Khan M, Lorenzo JM, et al. (2021) Recent advances in zinc oxide nanoparticles (Zno nps) for cancer diagnosis, target drug delivery, and treatment. *Cancers* 13: 4570.
10. Astefanei A, Núñez O, Galceran MT (2015) Characterisation and determination of fullerenes: a critical review. *Anal Chim Acta* 882: 1-21.